Inhatarget Therapeutics

Active

Private limited companyfounded 20197 yrs activeRue Antoine de Saint-Exupéry 2, 6041 Charleroi, BelgiumKBO/BCE: BE 0732.994.752

Inhatarget Therapeutics has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €2.16M and a net result of €-833k. Equity is shrinking by ~4.6% per year across the filed fiscal years. Its solvency ranks better than 70% of 242 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 1.0% (low).

Watch Print / PDF

Checked score

Score 2024

60 / 100

Healthy= vs 2023

The score combines four axes. Every signal that weighs is under Signals.

Axes · tick = 2023

Profitability0=

Solvency100=

Growth32=

Stability100

Bankruptcy probability, 12 months

1.0% Low

0%0.5%1.5%4%10%≥ 25%

Credit up to €130k at 30 days acceptable

Liquidity ample (current ratio 3.37 against 5.81 in 2023), and 26.8% of the assets are financed with debt.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Lower-failure-rate sector

In this sector companies fail less often than the Belgian average.

Gazette · bankruptcies per sector, NACE 72

Relative position

BE, all sectors

reference

Sector 72

lower

← fewer bankruptcies more bankruptcies →

Annual accounts: weaker financial profile

The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.

NBB · annual accounts 2024

Solvency, return and age of the figures

Solvency

73.2%

Return on assets

-28.2%

Age of the figures

20 mo

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Persistent losses

Two consecutive loss-making years (2023 and 2024); equity fell accordingly. May indicate structural pressure on profitability.

NBB · annual accounts 2024

Net result per financial year

2021222324

2020 to 2024 · latest year -€833k

Latest accounts filed on time

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 27-06-2025, 34 days ahead of the deadline.

NBB · 5 filings

Deviation from the deadline

2025

not confirmed

2024

34 d early

2023

30 d early

2022

34 d early

2021

39 d early

2020

33 d early

← before the deadline after the deadline →

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2024, full schema

Turnover

Not included in this filing

EBIT margin

Not included in this filing

Net result

€-833k▲ 9.8%

2023 · €-923k

2020: €-597k 2021: €-1.01M 2022: €-1.55M 2023: €-923k

2020 → 2024

Working capital

€1.88M▼ 32.4%

2023 · €2.78M

2020: €3.02M 2021: €1.96M 2022: €3.70M 2023: €2.78M

2020 → 2024

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20202021202220232024Trend

Equity€3.05M-€2.05M▼ 33.0%€3.84M▲ 87.7%€2.98M▼ 22.5%€2.16M▼ 27.3%

Operating result€-1.22M-€-1.87M▼ 54.1%€-3.26M▼ 74.0%€-2.01M▲ 38.5%€-2.05M▼ 2.1%

Net result€-597k-€-1.01M▼ 68.5%€-1.55M▼ 54.0%€-923k▲ 40.4%€-833k▲ 9.8%

Result per fiscal year

Operating resultNet result

The operating result stays negative: a loss of €2.05M in 2024 against €2.01M in 2023; the loss grows.

Balance-sheet composition

2024 in colour, 2023 as the grey bar beneath

Assets €2.96M

10%

90.3%

Fixed assets €288k▲ 43.9%

Current assets €2.67M▼ 20.4%

Equity and liabilities €2.96M

73.2%

26.8%

Equity €2.16M▼ 27.3%

Debt €793k▲ 37.1%

The debt ratio rises from 16.3% to 26.8%: debt grows while equity shrinks.

Key figures and ratios

2024 value · change against 2023

EBITDA

€-332k▼

2023 · €-280k

Cash flow

€884k▲

2023 · €803k

Solvency

73.2%▼

2023 · 83.7%

Current ratio

3.37▼

2023 · 5.81

Quick ratio

3.37▼

2023 · 5.81

Debt / equity

0.37▲

2023 · 0.19

ROE

-38.5%▼

2023 · -31.0%

ROA

-28.2%▼

2023 · -26.0%

Interest coverage

-103.12▲

2023 · -114.13

Debt

€793k▲

2023 · €579k

Debt ≤ 1 year

€791k▲

2023 · €577k

Income taxes

€-104k

Staff costs

€398k▲

2023 · €353k

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2024 against 2023

Balance sheet Code20232024

Assets

Total assets20/58€3.55M€2.96M▼

Fixed assets21/28€200k€288k▲

Intangible fixed assets21€193k€283k▲

Tangible fixed assets22/27€7k€5k▼

Plant, machinery and equipment23€5k€3k▼

Furniture and vehicles24€1k€1k▼

Financial fixed assets28€150€450▲

Current assets29/58€3.35M€2.67M▼

Amounts receivable within one year40/41€262k€229k▼

Other amounts receivable41€262k€229k▼

Current investments50/53€2.85M€1.75M▼

Cash at bank and in hand54/58€214k€676k▲

Deferred charges and accrued income490/1€28k€14k▼

Equity and liabilities

Total equity and liabilities10/49€3.55M€2.96M▼

Equity10/15€2.98M€2.16M▼

Contributions10/11€3.84M€3.84M=

Profit (loss) carried forward14€-923k€-1.76M▼

Investment grants15€57k€78k▲

Amounts payable17/49€579k€793k▲

Amounts payable within one year42/48€577k€791k▲

Trade debts44€149k€222k▲

Suppliers440/4€149k€222k▲

Taxes, remuneration and social security45€47k€54k▲

Remuneration and social security454/9€47k€54k▲

Other amounts payable47/48€381k€514k▲

Accrued charges and deferred income492/3€2k€2k▲

Income statement Code20232024

Remuneration, social security and pensions62€353k€398k▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.73M€1.72M▼

Other operating charges640/8€960€1k▲

Non-recurring operating charges66A€92-

Gross operating margin9900€75k€67k▼

Operating profit (loss)9901€-2.01M€-2.05M▼

Financial income75/76B€1.09M€1.11M▲

Recurring financial income75€1.09M€1.11M▲

Financial charges65/66B€2k€3k▲

Recurring financial charges65€2k€3k▲

Profit (loss) for the period before taxes9903€-923k€-937k▼

Income taxes67/77-€-104k

Profit (loss) for the period9904€-923k€-833k▲

Profit (loss) for the period to be appropriated9905€-923k€-833k▲

Appropriation of the result

Profit (loss) to be appropriated9906€-4.07M€-1.76M▲

Profit (loss) brought forward from the previous period14P€-3.15M€-923k▲

Transfer from equity791/2€3.15M-

Social balance

Average headcount (FTE)90875.55.8▲

The notes to these accounts (16 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 6Financial 1Filings 5

2025

27-06

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

01-07

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

27-06

NBB filing Annual accounts filed

fiscal year 2022 · full schema

2022

31-12

Financial Weakest financial yearnet €-1.55M

Net result drops to €-1.55M, the lowest in the series; recovery starts the following year.

22-06

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

28-06

NBB filing Annual accounts filed

fiscal year 2020 · full schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

no sitting director, no change since 2025

We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.

26-05-2025 S&F Holding: Resigned as Director

09-12-2024 50° NORTH VENTURES: Resigned as Director

10-09-2024 SMB Technology: Resigned as Director

01-01-2024 50° NORTH VENTURES: Resigned as Director

29-05-2020 Rémi Rosière: Resigned as Director

29-05-2020 THEODORUS IV: Resigned as Director

31-01-2020 GALEPHAR PHARMACEUTICAL RESEARCH INC: Resigned as Director

Location & real-estate footprint

Registered office, Charleroi · 1 establishment unit since 2019

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Antoine de Saint-Exupéry 26041 Charleroi